ArticleNature communications2022
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 56 citations in OpenAlex.
- Cardiac reprogramming via transient overexpression of P-glycoprotein alleviates doxorubicin-induced cardiotoxicity in mice and pigs.Nature communications · 2026Article
- A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity.Nature biomedical engineering · 2026Article
- Engineered internal architecture of core-shell lipid nanoparticles promotes efficient mRNA endosomal release.Nature communications · 2026Article
- Advances in T cell-based immunotherapy for osteosarcoma.Frontiers in immunology · 2026Review
- Building a coronavirus disease 2019 healthcare registry in an evolving pandemic.Scientific reports · 2025Article
- Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.Communications medicine · 2025Article
- Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.Journal of virology · 2024Article
- Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer.Molecular therapy. Nucleic acids · 2024Article
- Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern.Vaccines · 2024Article
- Mapping the Evolutionary Space of SARS-CoV-2 Variants to Anticipate Emergence of Subvariants Resistant to COVID-19 Therapeutics.PLoS computational biology · 2024Article
- Review
- Genetic and functional correction of argininosuccinate lyase deficiency using CRISPR adenine base editors.American journal of human genetics · 2024Article
- Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.Viruses · 2024Article
- Article
- Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity.Vaccines · 2024Review
- Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model.Scientific reports · 2024Article
- Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023).Human vaccines & immunotherapeutics · 2023Article
- Survey of white-footed mice (Peromyscus leucopus) in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses.Npj viruses · 2023Article
- Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.Journal of virology · 2023Article
Corrections and comments
- Update of
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
Abstract
The Omicron variant of SARS-CoV-2 recently swept the globe and showed high level of immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA vaccine candidate, and test its activity in animals, both alone and as a heterologous booster to WT mRNA vaccine. Our Omicron-specific LNP-mRNA vaccine elicits strong antibody response in vaccination-naïve mice. Mice that received two-dose WT LNP-mRNA show a > 40-fold reduction in neutralization potency against Omicron than WT two weeks post boost, which further reduce to background level after 3 months. The WT or Omicron LNP-mRNA booster increases the waning antibody response of WT LNP-mRNA vaccinated mice against Omicron by 40 fold at two weeks post injection. Interestingly, the heterologous Omicron booster elicits neutralizing titers 10-20 fold higher than the homologous WT booster against Omicron variant, with comparable titers against Delta variant. All three types of vaccination, including Omicron alone, WT booster and Omicron booster, elicit broad binding antibody responses against SARS-CoV-2 WA-1, Beta, Delta variants and SARS-CoV. These data provide direct assessments of an Omicron-specific mRNA vaccination in vivo, both alone and as a heterologous booster to WT mRNA vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.